Locally Advanced Breast Cancer clinical trials

Explore recruiting locally advanced breast cancer clinical trials.

Recruiting locally advanced breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Locally Advanced Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer

Poland, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

France, Spain, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - The p53 breast cancer trial

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)

France, Netherlands, Germany, Denmark, Spain, Sweden +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

CT7001_002 (SUMIT-BC) - An open-label Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant with or without Samuraciclib in Participants with Metastatic or Locally Advanced Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Spain, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)

Spain, Germany, Italy, Austria, Belgium, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Locally Advanced Breast Cancer trials by city

Locally Advanced Breast Cancer in Toronto Locally Advanced Breast Cancer in Vancouver Locally Advanced Breast Cancer in Montreal Locally Advanced Breast Cancer in Calgary Locally Advanced Breast Cancer in Edmonton Locally Advanced Breast Cancer in Ottawa Locally Advanced Breast Cancer in Winnipeg Locally Advanced Breast Cancer in Quebec City Locally Advanced Breast Cancer in Hamilton Locally Advanced Breast Cancer in Kitchener Locally Advanced Breast Cancer in London Locally Advanced Breast Cancer in Halifax Locally Advanced Breast Cancer in New York Locally Advanced Breast Cancer in Los Angeles Locally Advanced Breast Cancer in Chicago Locally Advanced Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease